Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
- Conditions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT00717587
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 472
- Registration Number
- NCT00716820
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1674
- Registration Number
- NCT00716625
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00715442
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2008-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT00712504
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
A Study for Participants With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 17
- Registration Number
- NCT00709995
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland
Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Tony Bekaii-Saab
- Target Recruit Count
- 25
- Registration Number
- NCT00702884
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1075
- Registration Number
- NCT00699374
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1520
- Registration Number
- NCT00700258
- Locations
- 🇩🇪
Office of Detlef Muller, Bautzen, Germany
🇩🇪Klotz, Weiden, Germany
🇩🇪Carsten Lange, Bernburg, Germany
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 130
- Registration Number
- NCT00698815
- Locations
- 🇺🇸
University of Vermont College of Medicine, Burlington, Vermont, United States
🇺🇸Iredell Memorial Hospital, Statesville, North Carolina, United States
🇺🇸Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.